From Curiosity to Global Impact

Luke O’Neill’s early fascination with interleukin-1, a key immune molecule, sparked a lifelong pursuit of understanding inflammation and immune responses.

A world-class scientist, Luke has built his career in Ireland. He is renowned for excellence in frontier research, engaging with the public, and winning several international prizes.

Driven by a passion for translational science, Luke has translated groundbreaking discoveries from his research in the university into real-world impact. Luke has successfully raised millions in capital for his ventures including three Irish spin-out biopharmaceutical companies – Opsona, Inflazome, and Sitryx.

Through his work, hundreds of scientists have been trained, as well as the identification of new potential drug candidates for treating a wide range of devastating diseases such as Parkinson’s, Alzheimer’s, and depression.

A breakthrough in his lab linking a particular protein to Type 2 diabetes paved the way for Inflazome, later acquired by Roche. Its drug candidates are now in clinical trials, showcasing how Irish research can lead globally with the potential to deliver transformative health solutions. Research Ireland’s support across career stages enables researchers like Luke to realise their ambitions.

It always strikes me how devastating a diagnosis can be for people. I want to give people hope. I want them to know scientists are working on options that could help in the future.

– Prof. Luke O’Neill, Trinity College Dublin

Partners:

Trinity College Dublin